Project Grant R01CA294638
Award Date 7/1/26
Completion Date 6/30/31
Dollars Obligated $697K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $421,685 project grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded August 1, 2025, with a completion date of July 31, 2027. This award supports research investigating the LIFR-LCN2 pathway as a novel mechanism of immune suppression in hepatocellular carcinoma (HCC). The research aims to elucidate how loss of LIFR upregulates LCN2, leading to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $421,685 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) for the period June 1, 2026, through May 31, 2028. This research initiative addresses methodological gaps in risk assessment for rare cancer patients by developing advanced statistical frameworks that leverage information from multiple data sources. The project will deliver two novel transfer-learning-based...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $616,715 to The University of Texas MD Anderson Cancer Center, with an award date of August 11, 2025 and completion date of July 31, 2030. This award supports research under the Cancer Treatment Research program (CFDA 93.395), which develops and evaluates improved methods of cancer treatment through fundamental and applied laboratory and clinical research. The funded research centers on the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $706,739 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 2, 2026, with a completion date of May 31, 2031. This award supports fundamental research to unravel the molecular mechanisms underlying immunotherapy-associated myocarditis (ICI-myocarditis), a severe cardiac inflammation that can occur as a side effect of immune checkpoint inhibitor (ICI) cancer...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $136,270 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The University of Texas MD Anderson Cancer Center, effective June 1, 2026 through May 31, 2031. This award supports research and training activities focused on dissecting the mechanisms by which messenger ribonucleic acid (mRNA) vaccines encoding non-tumor antigens initiate antitumor immunity in combination with immune checkpoint...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded MD Anderson Cancer Center a $688,073 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective June 1, 2026, through May 31, 2031. The award funds computational research to reconstruct the evolutionary history of cancer metastases, led by Principal Investigator Dr. Peter Van Loo. The project develops novel molecular archeology of cancer approaches—computational methods that leverage DNA sequencing...
- Federal Grant Award Summary The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center a $645,865 Project Grant under the Cancer Biology Research program (CFDA 93.396) beginning July 1, 2026, and concluding June 30, 2031. This five-year research initiative focuses on understanding and disrupting the neuroimmune feedback mechanisms that drive immunotherapy resistance in cutaneous squamous cell carcinoma (CSCC) with perineural invasion (PNI). The research will...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $660,541 to The University of Texas MD Anderson Cancer Center for research under the Cancer Biology Research program (CFDA 93.396). The award, effective April 1, 2026, through March 31, 2031, supports fundamental research on the modulation of the tumor microenvironment by Fusobacterium nucleatum (FN) and co-infecting microbial species in colorectal cancer (CRC). The research addresses a critical...
- Federal Project Grant Award Summary The University of Texas MD Anderson Cancer Center received a $370,173 Project Grant from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393), awarded September 9, 2025, with a completion date of August 31, 2030. This project delivers research and development of advanced genetic interaction measurement and characterization methodologies for cancer cells, with a primary focus on synthetic lethality as a...
- Federal Project Grant Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a $653,967 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective March 16, 2026, through February 28, 2031. This research initiative focuses on investigating the mechanistic basis and developing therapeutic strategies for PPP2R1A mutations in gynecological cancers, specifically uterine serous endometrial carcinoma and ovarian clear cell...